Program
DEP114
A development code.
Its studies are mostly in Rhinitis, Allergic, led by EMS.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| EMS | 22 open or running | phase 3since Feb 9, 2024 | Feb 9, 2024 | Dec 2028phase 3 · NCT07835074 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 9, 2024First study: phase 3 study in Rhinitis, AllergicFirst studyNCT06272409 · 318 planned
- Sep 15, 2026Phase 3 study in Persistent Allergic RhinitisNCT07835074 · 316 planned
Ahead
- Dec 2028Primary completion: phase 3 study in Persistent Allergic RhinitisNCT07835074
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07835074Persistent Allergic Rhinitis | 3 | Not yet recruiting | Dec 2028 | 316 |
| NCT06272409Rhinitis, Allergic | 3 | Not yet recruiting | Mar 15, 2025 | 318 |
How it is read
Names in the registry
- “DEP114”, 2 entries
Codes read as this program: DEP114.
Conditions, from the studies’ own filings
- Rhinitis, Allergic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.